{"id":"W3113031448","doi":"10.1016/j.annonc.2020.10.555","title":"67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"BeiGene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Clinical endpoint; Randomized controlled trial; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002480271,0.0001948683,0.0004760464,0.0002103766,0.000165643,0.0004878339,0.0001737231,0.0003715724,0.003772633],"category_scores_gemma":[0.0004777774,0.0001072712,0.0005699741,0.0001476743,0.0001265833,0.0003148375,0.0001658334,0.0005385451,0.0006253634],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004644094,"about_ca_system_score_gemma":0.0003474405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001594272,"about_ca_topic_score_gemma":0.002147536,"domain_scores_codex":[0.9998765,0.00002047402,0.000007189661,0.00003754109,0.00001468331,0.00004362766],"domain_scores_gemma":[0.9997658,0.00006671139,0.00004151649,0.00002461267,0.00001950009,0.00008182003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1755615,0.001818558,0.567638,0.0004521503,0.001214701,0.0006840721,0.0003035588,0.002271233,0.03599206,0.0004306466,0.01371983,0.1999138],"study_design_scores_gemma":[0.001504743,0.01705902,0.9709275,0.00004841531,0.0007961311,0.0004984093,0.0001278917,0.00118914,0.002591731,0.0002193229,0.005016024,0.00002165692],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951964,0.001256406,0.00006070791,0.00013686,0.00004073249,0.0000182184,0.001779999,0.0000189361,0.001491906],"genre_scores_gemma":[0.9937859,0.000329456,0.0000435351,0.0001342519,0.00003218581,0.00002199995,0.003454586,0.000007482492,0.002190589],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003772633,"threshold_uncertainty_score":0.01262075,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1554489825266507,"score_gpt":0.42046484643018,"score_spread":0.2650158639035293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}